Trial Profile
To evaluate early efficacy of Ibrutinib in patients with relapsed/refractory B-cell Chronic Lymphocytic Leukemia (CLL) : A real life Krohem Cll2 study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Sep 2016
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 02 Sep 2016 New trial record